Teratogenic Effects of Thalidomide: Molecular Mechanisms

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2011 Jan 6

PMID 21207098

Citations 53

Authors

Takumi Ito

Hideki Ando

Hiroshi Handa

Affiliations

Soon will be listed here.

Abstract

Fifty years ago, prescription of the sedative thalidomide caused a worldwide epidemic of multiple birth defects. The drug is now used in the treatment of leprosy and multiple myeloma. However, its use is limited due to its potent teratogenic activity. The mechanism by which thalidomide causes limb malformations and other developmental defects is a long-standing question. Multiple hypotheses exist to explain the molecular mechanism of thalidomide action. Among them, theories involving oxidative stress and anti-angiogenesis have been widely supported. Nevertheless, until recently, the direct target of thalidomide remained elusive. We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity. Our data suggest that thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting its ubiquitin ligase activity. In this review, we summarize the biology of thalidomide, focusing on the molecular mechanisms of its teratogenic effects. In addition, we discuss the questions still to be addressed.

Citing Articles

Molecular glue degrader for tumor treatment.

Hu Y, Yan Y, Wang J, Hou J, Lin Q Front Oncol. 2025; 14:1512666.

PMID: 39759140 PMC: 11697593. DOI: 10.3389/fonc.2024.1512666.

Optical directional differential operation enabled visual chirality detection.

Zhang Y, Wang M, Jiang T, Wen Z, Xiao J, Luo Z Biomed Opt Express. 2024; 15(9):5349-5358.

PMID: 39296409 PMC: 11407251. DOI: 10.1364/BOE.531056.

Limb reduction in an Esco2 cohesinopathy mouse model is mediated by p53-dependent apoptosis and vascular disruption.

Strasser A, Gonzalez-Reiche A, Zhou X, Valdebenito-Maturana B, Ye X, Zhang B Nat Commun. 2024; 15(1):7154.

PMID: 39168984 PMC: 11339411. DOI: 10.1038/s41467-024-51328-3.

Harnessing immunity: Immunomodulatory therapies in COVID-19.

Velikova T, Valkov H, Aleksandrova A, Peshevska-Sekulovska M, Sekulovski M, Shumnalieva R World J Virol. 2024; 13(2):92521.

PMID: 38984079 PMC: 11229839. DOI: 10.5501/wjv.v13.i2.92521.

()-3-aminopiperidine-2,6-dione is a biosynthetic intermediate of microbial blue pigment indigoidine.

Zhang Z, Li P, Wang M, Zhang Y, Wu B, Tao Y mLife. 2024; 1(2):146-155.

PMID: 38817675 PMC: 10989907. DOI: 10.1002/mlf2.12023.

References

Leslie N, Downes C . PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382(Pt 1):1-11. PMC: 1133909. DOI: 10.1042/BJ20040825. View

Makonkawkeyoon S, Moreira A, Schauf V, Kaplan G . Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1993; 90(13):5974-8. PMC: 46849. DOI: 10.1073/pnas.90.13.5974. View

Eriksson T, Bjorkman S, Roth B, Hoglund P . Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000; 52(7):807-17. DOI: 10.1211/0022357001774660. View

MELLIN G, KATZENSTEIN M . The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962; 267:1184-92 contd. DOI: 10.1056/NEJM196212062672305. View

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y . Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-50. DOI: 10.1126/science.1177319. View

Sauer H, Gunther J, Hescheler J, Wartenberg M . Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol. 2000; 156(1):151-8. PMC: 1868638. DOI: 10.1016/S0002-9440(10)64714-1. View

Grotewold L, Ruther U . The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J. 2002; 21(5):966-75. PMC: 125884. DOI: 10.1093/emboj/21.5.966. View

Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H . Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec. 2009; 9(1):66-85. DOI: 10.1002/tcr.20170. View

Grandel H, Schulte-Merker S . The development of the paired fins in the zebrafish (Danio rerio). Mech Dev. 1999; 79(1-2):99-120. DOI: 10.1016/s0925-4773(98)00176-2. View

10.

Vogelsang G, Farmer E, Hess A, Altamonte V, Beschorner W, Jabs D . Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992; 326(16):1055-8. DOI: 10.1056/NEJM199204163261604. View

11.

List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D . Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352(6):549-57. DOI: 10.1056/NEJMoa041668. View

12.

Tanaka M, Munsterberg A, Anderson W, Prescott A, Hazon N, Tickle C . Fin development in a cartilaginous fish and the origin of vertebrate limbs. Nature. 2002; 416(6880):527-31. DOI: 10.1038/416527a. View

13.

Parman T, Wiley M, Wells P . Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999; 5(5):582-5. DOI: 10.1038/8466. View

14.

Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C . Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010; 16(4):420-8. DOI: 10.1038/nm.2131. View

15.

Field H, Dong P, Beis D, Stainier D . Formation of the digestive system in zebrafish. II. Pancreas morphogenesis. Dev Biol. 2003; 261(1):197-208. DOI: 10.1016/s0012-1606(03)00308-7. View

16.

Castilla E, Ashton-Prolla P, Brunoni D, Cavalcanti D, Delgadillo J, Dutra M . Thalidomide, a current teratogen in South America. Teratology. 1996; 54(6):273-7. DOI: 10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#. View

17.

Lu J, Palmer B, Kestell P, Browett P, Baguley B, Muller G . Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res. 2003; 9(5):1680-8. View

18.

Therapontos C, Erskine L, Gardner E, Figg W, Vargesson N . Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A. 2009; 106(21):8573-8. PMC: 2688998. DOI: 10.1073/pnas.0901505106. View

19.

Higgins J, Pucilowska J, Lombardi R, Rooney J . A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology. 2004; 63(10):1927-31. PMC: 1201536. DOI: 10.1212/01.wnl.0000146196.01316.a2. View

20.

Andritsos L, Johnson A, Lozanski G, Blum W, Kefauver C, Awan F . Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(15):2519-25. PMC: 4312490. DOI: 10.1200/JCO.2007.13.9709. View